Experimental cell therapy takes on Hard-to-Treat cancers
NCT ID NCT04898543
First seen Jan 07, 2026 · Last updated May 02, 2026 · Updated 17 times
Summary
This early-stage study tests a new treatment called M-CENK, made from a patient's own immune cells, combined with a drug called N-803. It is for people with advanced solid tumors that have not responded to other treatments. The main goal is to check if the treatment is safe and to see how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chan Soon-Shiong Institute for Medicine
El Segundo, California, 90245, United States
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
Conditions
Explore the condition pages connected to this study.